Ä¢¹½Ö±²„

Promising HIV-gel trial halted in Africa

A vaginal gel that researchers hoped would reduce new HIV cases in Africa has been found to make no difference to infection rates

Disappointing news for women in Africa this week: the US National Institutes of Health has containing tenofovir, a drug that fights HIV, as it was found to make no difference to infection rates.

The result is a setback following a positive result in 2009, when women using a similar gel cut their risk of infection by 39 per cent compared with a placebo.

The , which began two years ago in South Africa, Uganda and Zimbabwe has failed to repeat this success. Of 2000 women participating, 6 per cent have been infected with HIV regardless of whether they were using the gel or a placebo.

The way women applied the gel might be a factor. In the halted trial, women applied the gel once a day. In the earlier trial, women applied it before and after sex. ā€œIt could be that women weren’t using it close enough to the sex act itself,ā€ says at the University of Utah in Salt Lake City. ā€œIt’s not the end of the line for gels, but we do need to explain the latest result to inform what to do next.ā€

Topics: HIV and AIDS